Fig. 7: Heterologous AdC68-HATRBD booster enhances the humoral and cell-mediated immunity of licensed influenza vaccine. | npj Vaccines

Fig. 7: Heterologous AdC68-HATRBD booster enhances the humoral and cell-mediated immunity of licensed influenza vaccine.

From: An intranasal combination vaccine induces systemic and mucosal immunity against COVID-19 and influenza

Fig. 7

a Scheme of experiments. Mice (n = 5 per group) were intramuscularly immunized with 3 μg of QIV. Four weeks later, the prime-boost group received a heterogenous i.n. booster with 5 × 107 IFU of AdC68-HATRBD. Eight weeks post-vaccination, serum, BALF, spleens, and lungs were collected. b Serum pH1N1 HA-specific lgG antibody titers. c, d BAFL pH1N1 HA-specific lgG (c) and lgA (d) antibody titers. e, f IL-4- and IFN-γ-secreting T cells specific for HA pool in the spleens (f) and lungs (g) were measured by ELISPOT assay. g Representative ELISpot showing HA-specific cytokines-secreting T cells. Each dot represents one animal. Data are presented as mean ± SEM. Asterisks indicate significant difference between groups determined using one-way ANOVA with Tukey correction. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.

Back to article page